Atossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One Patient [Seeking Alpha]
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: Seeking Alpha
Atossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One Patient Summary Atossa Genetics moved up significantly last week after the FDA granted expanded access for its oral Endoxifen for Post-Mastectomy Treatment on a U.S. Breast Cancer Patient. ATOS has a Phase 2 Study open for enrollment; the nature of the study will mean quick turnaround between enrollment and results. The success of one expanded access patient increases the likelihood that more patients will be treated under this program. Assuming full dilution from the conversion of preferred shares and the exercise of warrants, ATOS should have a float just above 10 million shares. Atossa Genetics Inc. ( announcing company announced positive results Why does the market care this time around? Being granted FDA expanded access in December should have been considered a massive achievement for this microcap stock. The update in February disclosing no safety or tolerability issues and a reduction
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesGlobeNewswire
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenGlobeNewswire
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerGlobeNewswire
ATOS
Sec Filings
- 4/11/24 - Form 4
- 4/2/24 - Form 8-K/A
- 4/1/24 - Form 10-K
- ATOS's page on the SEC website